SCANCELL



SCANCELL
AGM presentation

November 2020

Dr Cliff Holloway – CEO
Dr Sally Adams – Development Director
Professor Lindy Durrant – CSO

LSE: SCLP.L





HARNESSING IMMUNOLOGY TO FIGHT DISEASE

Dr Cliff Holloway
CEO

DISCLAIMER

This date hereof. The presentation has not been independently verified and no representation or warranty, express or implied, is made or given by presentation has been prepared by Scancell Holdings plc (the "Company") for general information purposes only.

This presentation may not be copied, distributed, reproduced or passed on, directly or indirectly, in whole or in part, or disclosed by any recipient, to any other person (whether within or outside such person's organisation or firm) or published in whole or in part, for any purpose or under any circumstances.

None of the Company or any of its directors, officers, employees, agents, affiliates, representatives or advisers (together, "Affiliates") or any other person makes any representation or warranty, express or implied, as to the accuracy or completeness of the information or opinions contained in this presentation and no reliance should be placed on the accuracy, completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions.

To the fullest extent permitted by law, none of the Company, its Affiliates or any other person accepts any liability whatsoever for any errors, omissions or inaccuracies in such information or opinions or for any loss, cost or damage suffered or incurred howsoever arising, directly or indirectly, from any use of this presentation or its contents or otherwise in connection with the subject matter of this presentation or any transaction. The information contained in this presentation is not to be relied upon for any purpose whatsoever. All information presented or contained in this presentation is subject to verification, correction, amendment, completion and change without notice, and such information may change materially. In giving this presentation, none of the Company, its Affiliates or any other person, undertakes any obligation to amend, correct or update this presentation or to provide the recipient with access to any further information that may arise in connection with it, or to advise any person of changes in the information set forth in this presentation after the or on behalf of the Company or any of its parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person's respective Affiliates, as to, and no reliance should be placed on, the accuracy, completeness or fairness of the information or opinions contained in this presentation and no responsibility or liability is assumed by any such persons for any such information or opinions or for any errors or omissions. All information presented or contained in this presentation is subject to verification, correction, completion and change without notice. In giving this presentation, none of the Company or any of its parent or subsidiary undertakings, or the subsidiary undertakings of any such parent undertakings, or any of such person's respective Affiliates, undertakes any obligation to amend, correct or update this presentation or to provide the recipient with access to any further information that may arise in connection with it.

This presentation does not and is not intended to constitute or form part of, and should not be construed as, any offer, inducement, invitation, commitment or recommendation to purchase, sell or subscribe for any securities, services or products of the Company in any jurisdiction and neither the issue of the information nor anything contained in this presentation shall form the basis of or be relied upon in connection with, or act as an inducement to enter into, any investment activity. This presentation does not purport to contain all of the information that may be required to evaluate any investment in the Company or any of its securities and should not be relied upon to form the basis of, or be relied on in connection with, any contract or commitment or investment decision whatsoever. This presentation is not intended to provide complete disclosure upon which an investment decision could be made. The merit and suitability of an investment in the Company should be independently evaluated and any person considering such an investment in the Company is advised to obtain independent advice as to the legal, tax, accounting, financial, credit and other related advice prior to making an investment.

To the extent available, the data contained in this presentation has come from official or third party sources. Third party industry publications, studies and surveys generally state that the data contained therein have been obtained from sources believed to be reliable, but that there is no guarantee of the accuracy or completeness of such data. While the Company believes that each of these publications, studies and surveys has been prepared by a reputable source, the Company has not independently verified the data contained therein. In addition, certain of the data contained in this presentation come from the Company's own internal research and estimates based on the knowledge and experience of the Company's management in the market in which the Company operates. While the Company believes that such research and estimates are reasonable and reliable, they, and their underlying methodology and assumptions, have not been verified by any independent source for accuracy or completeness and are subject to change without notice. Accordingly, undue reliance should not be placed on any of the data contained in this presentation.

This presentation includes forward-looking statements and the words "expect", "anticipate", "intends", "plan", "estimate", "aim", "forecast", "project" and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the Company's results of operations, financial condition, liquidity, prospects, growth, strategies and the industry in which the Company operates, and include statements regarding the Company's planned pre-clinical studies and clinical trials, regulatory approval process, and demand for the Company's product candidates are subject to risks, uncertainties, and other factors that could cause actual results to differ materially from those suggested by the Company's forward-looking statements. The forward-looking statements in this presentation are based on numerous assumptions regarding the Company's present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behaviour of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Past performance should not be taken as an indication or guarantee of future results, and no representation or warranty, express or implied, is made regarding future performance. Except as required by applicable law or regulation, none of the Company, its Affiliates or any other person accepts undertakes any obligation to update or revise any forward-looking statements in this presentation, whether as a result of new information, future events or otherwise, or to update or to keep current any other information contained in this presentation. Accordingly, undue reliance should not be placed on the forward-looking statements, which speak only as of the date of this presentation.

DISCLAIMER CONT'D

The financial information contained in this presentation is based on publicly available historic financial information of the Company and is not intended to be a profit forecast or profit estimate under applicable rules. Due to rounding, numbers presented throughout this presentation may not add up precisely to the totals provided and percentages may not precisely reflect the absolute figures.

This presentation has not been approved by an authorised person in accordance with section 21 of the Financial Services and Markets Act 2000. As such this presentation is being made available only to and is directed only at: (a) persons outside the United Kingdom; (b) persons having professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "Order"); (c) members or creditors of the Company within the meaning of Article 43 of the Order or (d) high net worth bodies corporate, unincorporated associations and other persons falling with Article 49(2) (a) to (d) of the Order, and other persons to whom it may otherwise lawfully be communicated (all such persons together being referred to as "relevant persons"). This presentation must not be acted or relied upon by persons other than relevant persons. Any investment or investment activity to which this presentation relates is only available to, and will be engaged in only with, relevant persons. Any failure to comply with these restrictions constitutes a violation of the laws of the United Kingdom. This presentation is not for publication, release or distribution, directly or indirectly, and may not be taken or transmitted, in or into the United States, Australia, Canada, New Zealand, Japan, the Russian Federation, the Republic of Ireland or the Republic of South Africa or any other jurisdiction where to do so would be unlawful and may not be copied, forwarded, distributed or transmitted in or into the United States, Australia, Canada, New Zealand, Japan, the Russian Federation, the Republic of Ireland or the Republic of South Africa or any other jurisdiction where to do so would be unlawful. The distribution of this presentation in any other jurisdictions may be restricted by law and persons into whose possession this presentation comes should inform themselves about, and observe any such restrictions. Any failure to comply with such restrictions may constitute a violation of the laws of the United States, Australia, Canada, New Zealand, Japan, the Russian Federation, the Republic of Ireland or the Republic of South Africa or any other such jurisdiction.

This presentation and the information contained herein is not intended for publication or distribution in, and does not constitute an offer of securities in, the United States or to any U.S. person (as defined in Regulation S under the U.S. Securities Act of 1933, as amended), Australia, Canada, New Zealand, Japan, the Russian Federation, the Republic of Ireland or the Republic of South Africa or any other jurisdiction where such distribution or offer is unlawful.

Any reference to any provision of any legislation in this presentation shall include any amendment, modification, re-enactment or extension thereof.

By accessing this presentation, you agree to be bound by the foregoing limitations.

AGM ARRANGEMENTS IN LIGHT OF COVID-19 RESTRICTIONS

The Company continues to monitor the COVID-19 situation closely, including UK Government legislation and guidance and accordingly shareholders, advisers and other guests will not be allowed to attend the AGM in person. In light of these measures, the Board strongly encourages shareholders to vote by proxy in accordance with the instructions in the Notice of AGM dated 21st October 2020.

In order to provide shareholders with the opportunity to ask questions at the AGM, the Company has made the following arrangements:

- This recorded presentation by members the Company's management team outlining the Company's progress will be available from Company's website on Monday, 9th November.
- Shareholders will be given the opportunity to email questions to the Board which must be received by 10:00am GMT on Friday, 13th November. The email address for these questions is investor.enquiries@scancell.co.uk. Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory announcements.
- Shareholders will be able to dial into the formal AGM at 2pm GMT on Tuesday, 17th November. The phone number for the dial in will be available on the Company's website on the morning of the AGM.

DEVELOPMENT PIPELINE

IMMUNOBODY®

- **SCIB1:** Targets malignant melanoma. Phase 2 trial in patients receiving immune checkpoint inhibitor
- **SCIB2:** Targets solid tumours. Phase 1/2 trial with immune checkpoint inhibitor to be funded and sponsored by Cancer Research UK (CRUK)
- ***Cov-19:*** *Adaptation of approach to COVID-19*

MODITOPE®

- **Modi-1:** Phase 1/2 trial including breast, ovarian, renal and head & neck cancer planned for 1H'21
- **Modi-2:** Targets multiple solid tumours
- **TCR collaboration:** To clone and characterise T cell receptors (TCR) against Modi-1 specific epitopes

AvidiMab™ / TaG mAbs

- **Anti-glycan mAbs:** Monoclonal antibodies (mAbs) targeting tumour associated glycans (TaGs)
- **AvidiMab:** Broad potential for enhanced potency of mAbs
- **Research collaboration:** Target evaluation in other platform technologies/mAb formats



STRONG CASH POSITION

COMPLETED £48m CAPITAL RAISE POST PERIOD

- **£15m capital raise in August 2020 comprising:**
  - £5m subscription by Redmile Group
  - £5m convertible loan notes subscribed by Redmile Group*
  - £1m convertible loan notes subscribed by Vulpes Life Sciences Fund**
  - Placement of £2m*** (including £1m from Vulpes Life Sciences Fund)
  - Open Offer of up to £2m***
    - Issue Price per New Ordinary Share for the Subscription, Placing and Open Offer: 5.5p
    - Price of the Convertible Loan Note per new Ordinary Share: 6.2p

- **£33m capital raise in October/November 2020 comprising:**
  - £12.1m subscription by Redmile Group
  - £17.9m convertible loan notes subscribed by Redmile Group
  - Open Offer of up to £3m***
    - Issue Price per New Ordinary Share for the Subscription, Convertible Loan Notes and Open Offer: 13p

*Partially converted Nov'20 **Fully converted Oct'20 ***Significantly oversubscribed

USE OF PROCEEDS

Extend the utility of the Company's Moditope®, Immunobody® and AvidiMab™/TaG antibody products and platforms to accelerate and broaden its development pipeline of novel therapies

- Advance SCIB1, Modi-1 and COVID-19 vaccine through planned clinical trials
- Initiate and advance new and existing Immunobody® and Moditope® programmes, such as Modi-2, which is currently in pre-clinical development
- Expand the Company's resources and capabilities in development and clinical operations to expedite programmes to the clinic and broaden their potential clinical utility
- Build on existing antibody expertise to further advance the preclinical development of the TaG antibodies, including as antibody-drug conjugates ("ADC")
- Supplement the c.£2m Innovate UK funding for the rapid development of a COVID-19 vaccine
- Broaden the Company's intellectual property portfolio
- Ensure both optimal development and commercialisation strategies can be pursued and to limit the potential impact on the Company of economic pressures caused by COVID-19

COMMERCIAL POSITIONING

Three Pillars Supporting the Path to Commercial Success

Technology

- **Innovative technology platforms to generate novel therapies-**
- Impact on patient survival and meeting unmet medical need
- Durable immune responses
- Defined/broad eligible patient population
- Broad indication profile
- Defined safety profile (utility in combination strategies)
- Validation of underlying platform technology

Translation

- **Building research and development capabilities:**
- Clinical expertise
- Broadening pipeline
- Strengthening IP portfolio
- Extending platform technologies
- Partner identification
- Alliance management
- Strategic investment

Transaction

- **First or best in class products i.e. differentiated therapeutic targets and/or novel approaches to validated targets:**
- Defined clinical relevance
- Defined mode of action
- Well tolerated therapies in addition to standard of care, e.g. CPI
- Low cost of treatment

SCANCELL

Dr Sally Adams

Development Director

DEVELOPMENT UPDATE

SCIB1-002 CLINICAL STUDY

- Status at 2019 AGM
  - Agreement from Nottingham NHS Trust to reimburse Keytruda costs
  - Single UK site opened August 2019 for recruitment (Nottingham)
  - IND for SCIB1 withdrawn due to FDA queries over Ichor device

Nottingham University Hospital NHS Trust

- IND progress
  - Re-submitted IND December 2019
  - Approved January 2020

FDA U.S. FOOD & DRUG ADMINISTRATION

- Study SCIB1-002
  - Slow recruitment with single UK site open
  - Three additional UK sites selected
  - Oxford, Mount Vernon and Velindre hospitals
  - March 2020 coronavirus pandemic and national lockdown



SCIB1-002 RESTART

- MHRA and HRA clinical trial Covid-19 guidance
  - Covid-19 clinical trials prioritised
  - Many NHS staff re-deployed to frontline Covid-19 wards
  - NHS resource for cancer trials significantly reduced
  - Cancer trials paused; new ones unable to start
  - Advanced therapies (e.g., Keytruda) require an ICU bed on standby
  - No regulatory requirement to report pausing of recruitment as a temporary halt

NHS Health Research Authority

MHRA Regulating Medicines and Medical Devices

- SCIB1-002 restart
  - Protocol amendment submitted to regulatory authorities
  - Reduced clinic visits for patients; minimise risk of exposure to Covid-19
  - Remote monitoring of study by Sponsor
  - Restart as soon as amendment approved; early Q1 target
  - Early data available H2 2021



MODI-1 DEVELOPMENT

THREE DRUG SUBSTANCES = MODI-1 DRUG PRODUCTS







- Modi-1 conjugates - novel cutting-edge products
- Hydrophobic peptides
  - Challenging synthetic properties
  - Manufacturing
  - Analytical development

PolyPeptide GROUP

- Polypeptide Group (PPL) selected as GMP manufacturer for Drug Substances
- AMRI selected as GMP manufacturer to formulate Drug Products

amri
Complex Science. Expert Solutions.

MODI-1 DEVELOPMENT PROGRESS

- GMP manufacture of three Drug Substances successfully completed
  - Gram quantities of high purity products
  - Stability studies underway
- GMP manufacture of two Drug Products successfully completed
  - AV-Vim28cit
  - AV-Vim415cit
  - 2000+ vials of each for clinical trial and stability studies
- Formulation development for AV-Eno241cit ongoing
  - Formulation strategy identified
  - GMP manufacturing slot scheduled
- Analytical assays developed and validated for each product
- Formal GLP toxicity study completed; no evidence of any local or systemic toxicities reported
- Successful regulatory Scientific Advice meeting held with MHRA in February 2020
- On target for H1 2021 start for clinical trial



MODI-1 FORMULATION

Surgical mask **N95/FFP2 mask**



Sterile solutions for injection

- Filtered through 0.2 micron (200 nm) filter to ensure safety of product
- Non-soluble particles bigger than 200 nm

AV-Vim28cit and AV-Vim415cit

- GMP lyophilized material
- Soluble at required concentration (e.g., 1 mg/mL)



1 mg/mL sterile

AV-Eno241cit

- GMP lyophilized material
- Not fully soluble in same solvent composition

0 mg/mL sterile

MODI-1 AV-Eno241-cit FORMULATION



COVIDITY MANUFACTURING

- Drug Product is plasmid DNA based on ImmunoBody platform



- ImmunoBody SCIB1 used safely in Phase 1/2 melanoma clinical trial
- Rapid progression of pVaxDCSN to clinic; reduced preclinical toxicity testing required
- Cell bank manufacturing underway at Cobra Biologics
- GMP production and release scheduled for H1 2021
- Clinical trial scheduled H2 2021

CLINICAL TIMELINES



Professor Lindy Durrant

CSO

RESEARCH UPDATE

RESEARCH SUMMARY

ImmunoBody®

- COVID vaccine
- New patent incorporating Avidimab™

Moditope®

- Modi-1: TNBC, ovarian, renal and head and neck cancer
- Modi-2: homocitrullination (potentially lung, breast, colorectal, prostate and pancreatic)
- Modi-3: potential to treat tumour recurrence

Monoclonal antibodies

- FG129-ADC/Avidimab™
- FG27 Avidimab™ – gastric cancer
- FL134 CART- SCLC (small cell lung cancer)
- FG2811 T cell targetting mAb
- New platform AvidiMab™ developed to improve the avidity (potency) of any mAb and the direct killing ability of anti-glycan mAbs



TCR

- Technology developed, 8/24 screened with no response possibly due to low avidity CD4 response in unimmunised donors to modified antigens. This technology may need to wait for the clinical trial

FG129 – A GOOD ANTIBODY FOR DELIVERING POTENT DRUGS (ADC)



Antibody linked to drug (ADC)



Internalisation to lysosomes to release drug



	CH129-vcE	CH129-DM1	CH129-DM4	Ritux-vcE	Ritux-DM1	Ritux-DM4
EC50	6.577e-011	1.961e-010	1.061e-010		~ 0.0004097	5.993e-009

ADC kills tumour cells *in vitro*



ADC clears human tumour growing as xenografts in nude mice

Published in Molecular Cancer Therapeutics

ImmunoBody® COVID-19 VACCINE

- The vaccine needs to stimulate neutralising antibodies to prevent viral entry
- Neutralising antibodies against the Spike (S) protein receptor-binding domain (RBD)
- The vaccine needs to stimulate T cells to kill virally infected cells
- T cell responses against the Nucleoprotein (N) which is conserved by many cornaviruses so can give broader protection and the RBD
- Avidimab™ modified Fc elicited strongest responses
- In collaboration with the UoN we are developing a simple non-toxic peptide delivery system to be as effective as electroporation





ImmunoBody® COVID-19 VACCINE CONSTRUCTS



	N construct	RBD construct
SN5		
SN6		
SN7		
SN8		
SN9		
SN10		
SN11		
SN12		
SN13		
SN14		
SN15		

11 DNA vaccines encoding combinations of the receptor binding domain of the S protein as small and large monomers, trimers and C-C dimers in combination with N protein or N protein fused to Fc or modified Fc to target high affinity FcγR1(CD64) on activated dendritic cells

Fc-RECEPTOR BINDING DOMAIN INDUCED MOST POTENT T CELL RESPONSE PLUS A STRONG ANTIBODY RESPONSE

T cells







Virus neutralising antibodies



Small RBD and C-C constructs failed to stimulate antibody responses, large RBD monomer gave strongest antibody response and RBD-Fc gave strongest T cell response

MODIFIED Fc-N PROTEIN INDUCED THE STRONGEST T CELL RESPONSE



N protein



N aa138-146



AVIDIMAB-ENHANCED Fc UPTAKE



- Increases avidity of Fc-fusions by promoting non-covalent Fc-Fc interactions
- Promotes uptake and presentation of Class I and Class II epitopes

New patent for all ImmunoBody®

AGM ARRANGEMENTS

- Questions to the Board from shareholders must be received by email by 10:00am GMT on Friday, 13th November
- The email address for these questions is investor.enquiries@scancell.co.uk
- Whilst the Company may not be in a position to answer every question it receives, it will address the most prominent within the confines of information already disclosed to the market through regulatory announcements
- Shareholders will be able to dial into the formal AGM at 2:00pm GMT on Tuesday, 17th November
- The phone number for the dial in will be available on the Company's website on the morning of the AGM

SCANCELL

Thank you…